Lars Wortmann

Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction

R.C. Hillig, Brice Sautier, Jens Schroeder et al. · Proceedings of the National Academy of Sciences · 2019 · 379 citations · Full text

Medicine, Molecular Biology, Oncology +17

The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models

Antje M. Wengner, Gerhard Siemeister, Ulrich Lücking et al. · Molecular Cancer Therapeutics · 2019 · 210 citations

Medicine, Molecular Biology, Oncology +17

Use of the Novel Plk1 Inhibitor ZK-Thiazolidinone to Elucidate Functions of Plk1 in Early and Late Stages of Mitosis

Anna Santamaría, Rüdiger Neef, Uwe Eberspächer et al. · Molecular Biology of the Cell · 2007 · 198 citations

Life Sciences, Cell Biology, Oncology +17

Recovery of Carbonyl Compounds from <i>N</i>,<i>N</i>-Dialkylhydrazones

Dieter Enders, Lars Wortmann, René Peters · Accounts of Chemical Research · 2000 · 127 citations

Pharmacy, Chemistry, Medicinal Chemistry +10

Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models

Ulrich Lücking, Lars Wortmann, Antje M. Wengner et al. · Journal of Medicinal Chemistry · 2020 · 71 citations · Full text

Medicine, Medicinal Chemistry, Oncology +13